Caris Life Sciences

Historical price data

Founded in 2008, Caris Life Sciences has established itself as a pioneer in precision oncology, combining whole exome sequencing, whole transcriptome sequencing, and proteomic analysis with sophisticated AI algorithms. The company has processed over 1 million cases, performed 6.5+ million tests, and built a database of 740,000+ matched molecular and clinical outcomes records. Caris serves three key markets: patients seeking personalized treatment options, physicians requiring molecular blueprints for clinical decisions, and biopharma companies needing translational medicine and clinical development support. Their continuum of care spans disease detection, therapy selection, and treatment monitoring.

Caris integrates whole exome sequencing, whole transcriptome sequencing, and proteomic analysis with artificial intelligence algorithms to create comprehensive molecular blueprints for cancer patients, supported by one of the world's largest multimodal molecular and clinical outcomes databases.

2 drugs in pipeline

Total raised: $685M

Caris competes with comprehensive molecular profiling companies like Foundation Medicine (Roche) and Guardant Health, as well as emerging AI-driven platforms like Tempus. Differentiation comes from Caris's multimodal approach (DNA+RNA+protein), massive clinical-molecular database (740,000+ records), and extensive physician network through the Precision Oncology Alliance™ (95+ members including 45+ NCI centers).